Madrigal Pharmaceuticals, Inc.

MDGL Nasdaq SEC CIK 1157601
Follow Madrigal Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $431.3M +50.1% vs same quarter last year
Net income $55.4M +148.6% vs same quarter last year
EPS, diluted $1.83 +145.6% vs same quarter last year
Operating cash flow $120.6M +51% vs same quarter last year
Revenue by quarter
$103.3M
$137.3M
$212.8M
$287.3M
$321.1M
$311.3M
$364.3M
$431.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$500M$0$500M$1BFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$958.4M−$288.3M
FY24$180.1M−$465.9M
FY23$0−$373.6M
FY22$0−$295.3M
FY21$0−$241.8M
FY20$0−$202.2M
FY19$0−$83.9M
FY18$0−$32.8M
FY17$0−$31.2M
FY16-−$26.4M
FY15-−$6.8M
FY14-−$86.2M
FY13-−$90.2M
FY12$147K−$62.8M
FY11-−$47.4M
MarginsShare of revenue
  • Operating margin
  • Net margin
−60000%−40000%−20000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−31.3%−30.1%
FY24−276.4%−258.6%
FY23--
FY22--
FY21--
FY20--
FY19--
FY18--
FY17--
FY16--
FY15--
FY14--
FY13--
FY12−41456.5%−42714.3%
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$600M−$400M−$200M$0FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$190M
FY24−$457M
FY23−$325.7M
FY22−$225.1M
FY21−$184.1M
FY20−$157.9M
FY19−$41.8M
FY18−$25.5M
FY17−$22.4M
FY16−$17.6M
FY15−$3.2M
FY14−$79.1M
FY13−$78.2M
FY12−$54.6M
FY11−$48M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Madrigal Pharmaceuticals
  • Healthcare median
−60000%−40000%−20000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearMadrigal PharmaceuticalsHealthcare median
FY25−30.1%−30.6%
FY24−258.6%−47%
FY23-−58%
FY22-−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%
FY12−42714.3%−29.1%
FY11-−27.9%